Collaborating Institutions and Societies
Disruptive gene therapy, with a 360º view of Alzheimer’s disease. A unique multifactorial therapy that is being developed at present.
Endorsed by some highly satisfactory preliminary results, our therapy is in the regulatory preclinical phase. Our road map has been validated by the AEMPS and submitted to the EMA.
Intellectual property protection in the U.S.A, Japan and Europe. Currently, over 50 million people suffer from this devastating neurodegenerative disease.
A scientific team with over 30 years’ experience in neuroscience. We have an expert management team and an advisory team made up of representatives from the pharmaceutical industry.